Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.

Abstract:

:Despite the significant progresses made in antiretroviral therapy, current drugs still cannot cure or prevent HIV infection. And all drugs continue to select for drug-resistant HIV strains. Consequently, new antiretroviral drugs are constantly being developed. To ensure safety, these drugs are usually designed to inhibit viral proteins. But cellular proteins are also emerging as potential targets for new antiretroviral drugs. Two drugs that target cellular proteins inhibit HIV replication in vitro, hydroxyurea (HU) and pharmacological cyclin-dependent kinase inhibitors (PCIs). HU has been tested in clinical trials, commonly in combination therapies. PCIs, which are newer drugs, have just started to be tested in animal models of HIV-induced disease. Herein, we will review the HIV replication cycle and discuss the biological causes why strains resistant to antiviral drugs are so easily selected for. We will then discuss current antiretroviral drugs and HU before focusing on PCIs. PCIs have demonstrated to be effective against wild-type and drug-resistant strains of HIV in vitro, while selecting for no drug resistance. PCIs are additive with conventional antiviral drugs against herpes simplex virus, which suggests that they could also be additive with antiretroviral drugs. Since PCIs are proving surprisingly safe in human clinical trials (against cancer), they may be developed as clinical antiretroviral drugs in the near future. Recent and exciting studies indicate that PCIs ameliorate the pathogenesis of an animal model of HIV-induced nephropathy. We can expect that the full potential of PCIs as antiretroviral drugs will be explored in the coming years.

journal_name

Curr Pharm Des

authors

Provencher VM,Coccaro E,Lacasse JJ,Schang LM

doi

10.2174/1381612043382422

subject

Has Abstract

pub_date

2004-01-01 00:00:00

pages

4081-101

issue

32

eissn

1381-6128

issn

1873-4286

journal_volume

10

pub_type

杂志文章,评审
  • Central hemodynamics for risk reduction strategies: additive value over and above brachial blood pressure.

    abstract::Reduction strategies of blood pressure, as a modifiable cardiovascular risk, are currently based on office assessment of brachial artery blood pressure. However, antihypertensive treatment based on brachial BP values reduces cardiovascular risk but cannot completely reverse the hypertension-induced risk of morbidity e...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666141023164530

    authors: Rinaldi ER,Yannoutsos A,Borghi C,Safar ME,Blacher J

    更新日期:2015-01-01 00:00:00

  • Raloxifene and cardiovascular health: its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women.

    abstract::CHD is one of the most common serious chronic conditions in postmenopausal women and leads to extremely high risk for recurrent myocardial infarction and death. On the basis of the currently available randomized clinical-trial results the role of conventional HRT for treatment and prevention of CHD is rapidly evolving...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161205774913237

    authors: Francucci CM,Camilletti A,Boscaro M

    更新日期:2005-01-01 00:00:00

  • FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA.

    abstract::Guanine-rich sequences found in telomeres and oncogene promoters have the ability to form G-quadruplex structures. In this paper we describe the use of a virtual screening assay to search a database of FDA-approved compounds for compounds with the potential to bind G-quadruplex DNA. More than 750 telomerase inhibitors...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612811319120004

    authors: Castillo-González D,Pérez-Machado G,Guédin A,Mergny JL,Cabrera-Pérez MA

    更新日期:2013-01-01 00:00:00

  • Contribution of Nanotechnology to Improved Treatment of Periodontal Disease.

    abstract::Periodontal disease is chronic inflammation of periodontal tissues resulting in formation of periodontal pockets, periodontal attachment loss and progressive destruction of the ligament and alveolar bone. This review gives an update on periodontal disease pathogenesis, which is important for the development of novel m...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150531171829

    authors: Zupancic S,Kocbek P,Baumgartner S,Kristl J

    更新日期:2015-01-01 00:00:00

  • Agonist replacement for stimulant dependence: a review of clinical research.

    abstract::Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and cl...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161281940131209142843

    authors: Stoops WW,Rush CR

    更新日期:2013-01-01 00:00:00

  • Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?

    abstract::Neuroinflammation is a common characteristic of several mental health conditions such as major depression, bipolar disorder, post-traumatic stress disorder (PTSD) and schizophrenia (SCHZ). Inflammatory processes trigger and/or further deteriorate mental functions and are regarded as targets for therapeutic drug develo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161282210160304112511

    authors: Echeverria V,Grizzell JA,Barreto GE

    更新日期:2016-01-01 00:00:00

  • The gut mucosa as a site for induction of regulatory T-cells.

    abstract::Regulatory T lymphocytes (Tregs) are specialized for immune suppression and are important regulators of the immune response in various settings. Tregs actively suppress enteroantigen-reactive cells and contribute to the maintenance of intestinal immune homeostasis. Distinct Treg subsets coexist in the intestinal mucos...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209787846784

    authors: Mizrahi M,Ilan Y

    更新日期:2009-01-01 00:00:00

  • Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy.

    abstract::Fusion proteins have been well-studied and widely applied in biopharmaceutics. Albumin fusion proteins are simple to construct, easy to purify, and stable to formulate. One main application of fusion protein is to extend the plasma half-life of therapeutic proteins and peptides. Albiglutide for diabetes treatment is t...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150302120047

    authors: Rogers B,Dong D,Li Z,Li Z

    更新日期:2015-01-01 00:00:00

  • Bioactive peptides: are there more antihypertensive mechanisms beyond ACE inhibition?

    abstract::Diet has a high relevance in health. Hypertension is a major risk factor for cardiovascular diseases and has an important impact on public health, and consequently on countries economy. Scientific research gathered strong evidence about the role of several dietary factors either in etiology or in treatment/prevention ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212802651670

    authors: Marques C,Amorim MM,Pereira JO,Pintado ME,Moura D,Calhau C,Pinheiro H

    更新日期:2012-01-01 00:00:00

  • Activation of the Glutathione Peroxidase by Metformin in the Bile-duct Ligation induced Liver Injury: In vivo Combined with Molecular Docking Studies.

    abstract:BACKGROUND:Inhibition of hepatic fibrosis is an attainable objective in managing the chronic liver disease. The present study aimed to investigate possible defensive effects of metformin on the activities of antioxidant enzymes, hydroxyproline content, and biochemical factors in bile duct ligation (BDL)-induced cholest...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612824666181003114108

    authors: Mansourian M,Sadeghi H,Doustimotlagh AH

    更新日期:2018-01-01 00:00:00

  • Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?

    abstract::The disappointing results in long-term survival of patients affected by non-small cell lung cancer (NSCLC) may be attributed, at least in part, to the lack of knowledge on the way by which genetic characteristics in normal and neoplastic cells affect responsiveness as well as metabolism of chemotherapy and new targete...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/13816128113196660756

    authors: Galvani E,Toffalorio F,Peters GJ,De Pas T,Giovannetti E

    更新日期:2014-01-01 00:00:00

  • Rheumatoid arthritis: genetic variants as biomarkers of cardiovascular disease.

    abstract::Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with premature mortality, severe morbidity, and functional impairment leading to considerable financial burden for both patients and society. Since disease progression and complications can differ from one patient to another, genetic markers are of...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666140825123407

    authors: Rodriguez-Rodriguez L,López-Mejias R,Fernández-Gutiérrez B,Balsa A,González-Gay MA,Martín J

    更新日期:2015-01-01 00:00:00

  • The gut microbiota in inflammatory bowel disease.

    abstract::Crohn's disease and ulcerative colitis are the two principal forms of inflammatory bowel disease (IBD). The root causes of these chronic and acute immunological disorders are unclear, but intestinal microorganisms are known to play a key role in the initiation and maintenance of disease. However, at present, there is ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209788168146

    authors: Macfarlane GT,Blackett KL,Nakayama T,Steed H,Macfarlane S

    更新日期:2009-01-01 00:00:00

  • Global Effects of Early Life Stress on Neurons and Glial Cells.

    abstract::Early life stress is considered a risk factor for the development of many diseases in both adolescence and adulthood. It has been reported that chronic stress (for instance, due to maternal separation during breast feeding), causes damage to the central nervous system at the level of neurons and glial cells, which are...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170224111641

    authors: Duenas Z,Caicedo-Mera JC,Torner L

    更新日期:2018-02-12 00:00:00

  • The effect of Endovascular Aneurysm Repair on Renal Function in Patients Treated for Abdominal Aortic Aneurysm.

    abstract:AIM:The effect of endovascular aneurysm repair in patients treated for abdominal aortic aneurysm has not been clearly defined. The objective of the present article was to provide a contemporary literature review and perform an analysis to determine the effect of EVAR on renal function in the early post-operative period...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612825666191129094923

    authors: Nana P,Kouvelos G,Brotis A,Spanos K,Giannoukas A,Matsagkas M

    更新日期:2019-01-01 00:00:00

  • Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases.

    abstract::Pulmonary surfactant, a complex of lipids and proteins, functions to keep alveoli from collapsing at expiration. Surfactant proteins A (SP-A) and D (SP-D) belong to the collectin family and play pivotal roles in the innate immunity of the lung. Pulmonary collectins directly bind with broad specificities to a variety o...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206775474387

    authors: Takahashi H,Sano H,Chiba H,Kuroki Y

    更新日期:2006-01-01 00:00:00

  • Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

    abstract::P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization. Multiple lines of evidence suggest that the level of on-treatment platelet reactivity inhibition with P2Y12 ADP re...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212803251934

    authors: Laine M,Camoin-Jau L,Bessereau J,Sébastien A,Paganelli F,Bonello L

    更新日期:2012-01-01 00:00:00

  • Inflammatory process in Parkinson's disease: role for cytokines.

    abstract::Parkinson's disease (PD) is a movement disorder caused by degeneration of the nigrostriatal dopamine (DA) neurons in the substantia nigra pars compacta and the resultant deficiency in the neurotransmitter DA at the nerve terminals in the striatum. We and other investigators found increased levels of pro-inflammatory c...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612053381620

    authors: Nagatsu T,Sawada M

    更新日期:2005-01-01 00:00:00

  • Renin-angiotensin antagonists: therapeutic effects beyond blood pressure control?

    abstract::Guidelines for the treatment of hypertension allow a wide range of choices to the physicians; however some differences are present about the preferred drugs to start treatment. The most important aim remains an adequate decrease of blood pressure, something not perfectly obtained in the general population, but some cl...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212799436575

    authors: Pende A,Dallegri F

    更新日期:2012-01-01 00:00:00

  • Phase-change contrast agents for imaging and therapy.

    abstract::Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel ways of approaching diagnostic and therapeutic techniques beyond what is possible with microbubble contrast agents and liquid emulsions. When subjected to sufficient pressures delivered by an ultrasound transducer, stabilized...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212800099883

    authors: Sheeran PS,Dayton PA

    更新日期:2012-01-01 00:00:00

  • Combined use of Genetic Polymorphisms and Elastographic Techniques in NAFLD: Fact or Fiction?

    abstract::Non-alcoholic fatty liver disease (NAFLD) includes liver diseases ranging from simple steatosis to progressive forms characterized by high rates of complications and mortality, namely fibrosis, cirrhosis and hepatocellular carcinoma. Identification of patients with simple steatosis who will evolve to a more severe liv...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666191122101021

    authors: Lombardi R,Fargion S,Fracanzani AL

    更新日期:2020-01-01 00:00:00

  • Therapeutic effect of ghrelin in the course of ischemia/reperfusion-induced acute pancreatitis.

    abstract:BACKGROUND:Protective effect of pretreatment with ghrelin against different forms of acute pancreatitis (AP) has been recently reported. Moreover, the healing properties of this peptide have been proved in AP evoked by cerulein. However, no studies have investigated whether the administration of ghrelin affects the cou...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612821666150105152553

    authors: Bukowczan J,Warzecha Z,Ceranowicz P,Kusnierz-Cabala B,Tomaszewska R,Dembinski A

    更新日期:2015-01-01 00:00:00

  • Serotonergic system and its role in epilepsy and neuropathic pain treatment: a review based on receptor ligands.

    abstract::The serotonergic system is involved in pathomechanisms of both epilepsy and neuropathic pain. So far, participation in the epileptogenesis and maintenance of epilepsy was proved for 5-HT1A, 5-HT2C, 5-HT3, 5-HT4 and 5-HT7 receptors as well as 5-HTT serotonin transporter. Depending on the receptor type or its localizati...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666141121114917

    authors: Panczyk K,Golda S,Waszkielewicz A,Zelaszczyk D,Gunia-Krzyzak A,Marona H

    更新日期:2015-01-01 00:00:00

  • Machine learning methods in prediction of protein palmitoylation sites: A brief review.

    abstract::Protein palmitoylation is a fundamental and reversible post-translational lipid modification that involves a series of biological processes. Although a large number of experimental studies have explored the molecular mechanism behind the palmitoylation process, the computational methods has attracted much attention fo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666201112142826

    authors: Li Y,Pu F,Wang J,Zhou Z,Zhang C,He F,Ma Z,Zhang J

    更新日期:2020-11-12 00:00:00

  • Nanoparticle-Based Combination Therapy for Cancer Treatment.

    abstract::In recent years, combination of different types of therapies using nanoparticles has emerged as an advanced strategy for cancer treatment. Most of all, combination of chemotherapeutic drug and siRNA in nanoformulation has shown a great potential, because siRNA-mediated specific gene silencing can compensate for the in...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150531165059

    authors: Yhee JY,Son S,Lee H,Kim K

    更新日期:2015-01-01 00:00:00

  • AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs?

    abstract::Ischaemic stroke of the brain accounts for about one third of all deaths in industrialized countries. Many of the patients who survive are severily impaired. Thus, there is an enormous need for pharmacotherapy for the treatment of ischaemic stroke. Why is such a treatment not available yet? Are the pathophysiological ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612024607135

    authors: Weiser T

    更新日期:2002-01-01 00:00:00

  • LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics.

    abstract::Over the past decade, Lymphocyte Function-Associated Antigen-1 (LFA-1, alphaLbeta2, CD11a/CD18) has emerged as an attractive therapeutic target for the treatment of multiple inflammatory diseases. Its established role in the trafficking and activation of leukocytes coupled with the recent elucidation of the global con...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206777947731

    authors: Giblin PA,Lemieux RM

    更新日期:2006-01-01 00:00:00

  • Deubiquitinating enzymes as therapeutic targets in cancer.

    abstract::Abnormal regulation of the ubiquitin-proteasome system (UPS) has been known to be involved in the pathogenesis of a variety of human diseases. A number of studies have focused on the identification of small modifiers for the UPS. Even though the proteasome inhibitor Bortezomib (Velcade®) has been approved for the ther...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811319220013

    authors: Lim KH,Baek KH

    更新日期:2013-01-01 00:00:00

  • Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment.

    abstract::The last decades have witnessed an explosion in studies of the role of amyloid-β (Aβ) in the progress of the neurodegenerative disorder Alzheimer's disease (AD) and it is now widely accepted that Aβ is related to the pathogenesis of AD. For example, studies have shown that Aβ is neurotoxic and that the neurotoxicity o...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211797416039

    authors: Portelius E,Mattsson N,Andreasson U,Blennow K,Zetterberg H

    更新日期:2011-01-01 00:00:00

  • Effect of Capsinoids Supplementation on Fat Oxidation and Muscle Glycogen Restoration During Post-exercise Recovery in Humans.

    abstract:Background:Capsinoids (CSN), the novel non-pungent capsaicin analogs have been reported to promote metabolic health and exercise tolerance. However, the effect of CSN on fat oxidation and changes in skeletal muscle glycogen levels during post-exercise recovery has not been investigated in humans. Purpose:We examined t...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666200824104856

    authors: Liao SF,Korivi M,Tsao JP,Huang CC,Chang CC,Cheng IS

    更新日期:2020-08-23 00:00:00